HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Leslie Chong

Managing Director & Chief Executive Officer

Ms Chong most previously was a Senior Clinical Program Lead at Genentech, a member of the Roche family, in the head office in San Francisco. She has over 17 years of experience in leading clinical and department development in oncology. Most recently, she was the clinical operations program lead for the approved MEK inhibitor in cell-signalling targeted therapy, cobimetinib/Cotellic.

Prior to Genentech, Ms Chong was one of the clinical operation head at Exelixis, in development of 14 compounds and molecules. She has also been a member of the clinical operation department at GSK and PPD.

Leslie believes that early development and research innovation has the ability to bring transformative medicine to patients in need.

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551